Benralizumab for EGPA: a real-world study
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at how well benralizumab (Fasenra) works for people with EGPA, a rare disease that causes inflammation in blood vessels and can affect the lungs, skin, and nerves. By tracking people already on this treatment, researchers hope to learn more about its long-term effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of EGPA.
- You are currently receiving benralizumab 30 mg every 4 weeks.
- You have data available from at least 3 months of treatment with benralizumab.
- You can provide written permission (consent) to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
This study is for people with severe eosinophilic asthma who are about to start a medicine called Benralizumab (Fasenra). It will observe how the medicine works in real life, and requires you to answer some questions about your asthma every week and month.
This trial tests reslizumab, a medicine that targets a specific immune signal, to improve symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA). It may help lower disease activity and reduce inflammation-related problems.
This study follows people with severe eosinophilic asthma who are starting benralizumab. It looks at how well the treatment works in real life, outside of a controlled research setting.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
Hear when a new Eosinophilic Granulomatosis With Polyangiitis (EGPA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.